


<!DOCTYPE html>
<html lang="en">
<head><script src="//archive.org/includes/analytics.js?v=cf34f82" type="text/javascript"></script>
<script type="text/javascript">window.addEventListener('DOMContentLoaded',function(){var v=archive_analytics.values;v.service='wb';v.server_name='wwwb-app16.us.archive.org';v.server_ms=281;archive_analytics.send_pageview({});});</script><script type="text/javascript" src="/static/js/wbhack.js?v=1531166943.0" charset="utf-8"></script>

<script type="text/javascript">
__wbhack.init('https://web.archive.org/web');
</script>
<link rel="stylesheet" type="text/css" href="/static/css/banner-styles.css?v=1531166943.0" />
<link rel="stylesheet" type="text/css" href="/static/css/iconochive.css?v=1531166943.0" />

<!-- End Wayback Rewrite JS Include -->  

        <title>Upper tract urothelial tumours. | National Guideline Clearinghouse</title>

    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width">
    <link rel="icon" href="/web/20180712210624im_/https://www.guideline.gov/UI/images/favicon-NGC.ico">
    <link rel="apple-touch-icon" sizes="180x180" href="/web/20180712210624im_/https://www.guideline.gov/UI/images/apple-touch-icon-NGC.png">
    <link rel="icon" type="image/png" href="/web/20180712210624im_/https://www.guideline.gov/UI/images/favicon-NGC-32x32.png" sizes="32x32">
    <link rel="icon" type="image/png" href="/web/20180712210624im_/https://www.guideline.gov/UI/images/favicon-NGC-16x16.png" sizes="16x16">
    <link rel="manifest" href="/web/20180712210624/https://www.guideline.gov/UI/images/manifest-NGC.json">
    <link rel="mask-icon" href="/web/20180712210624im_/https://www.guideline.gov/UI/images/safari-pinned-tab-NGC.svg" color="#1d4345">
    <meta name="theme-color" content="#ffffff">
    
<link href="/web/20180712210624cs_/https://www.guideline.gov/cassette.axd/stylesheet/8382974d7bae1577062376dcd37102348398fe04/NGCSiteCSS" type="text/css" rel="stylesheet"/>
<!--[if lt IE 9]>
<link href="/cassette.axd/stylesheet/2188ac5b8507764bb4079068f7a3c8d7ccfba0e7/ieCSS" type="text/css" rel="stylesheet"/>
<![endif]-->



    <script async type="text/javascript" id="_fed_an_ua_tag" src="https://web.archive.org/web/20180712210624js_/https://dap.digitalgov.gov/Universal­-Federated-­Analytics-­Min.js?agency=HHS&amp;subagency=AHRQ"></script>
    </head>
<body class="no-js content-page">
<a href="#main-content" id="skip-nav">Skip to main content</a>
<!--https://developers.google.com/tag-manager/devguide#multidomain  ECH-1199-->
    
    <!-- Google Tag Manager -->
    <noscript>
        <iframe src="//web.archive.org/web/20180712210624if_/https://www.googletagmanager.com/ns.html?id=GTM-W4NX5V" height="0" width="0" style="display:none;visibility:hidden"></iframe>
    </noscript>
    <script>
        (function (w, d, s, l, i) {
            w[l] = w[l] || []; w[l].push({
                'gtm.start':
                new Date().getTime(), event: 'gtm.js'
            }); var f = d.getElementsByTagName(s)[0],
            j = d.createElement(s), dl = l != 'dataLayer' ? '&l=' + l : ''; j.async = true; j.src =
            '//web.archive.org/web/20180712210624/https://www.googletagmanager.com/gtm.js?id=' + i + dl; f.parentNode.insertBefore(j, f);
        })(window, document, 'script', 'dataLayer', 'GTM-W4NX5V');</script>

    <noscript>
        <iframe src="//web.archive.org/web/20180712210624if_/https://www.googletagmanager.com/ns.html?id=GTM-KHDP6Z" height="0" width="0" style="display:none;visibility:hidden"></iframe>
    </noscript>
    <script>
        (function (w, d, s, l, i) {
            w[l] = w[l] || []; w[l].push({
                'gtm.start':
                new Date().getTime(), event: 'gtm.js'
            }); var f = d.getElementsByTagName(s)[0],
            j = d.createElement(s), dl = l != 'dataLayer' ? '&l=' + l : ''; j.async = true; j.src =
            '//web.archive.org/web/20180712210624/https://www.googletagmanager.com/gtm.js?id=' + i + dl; f.parentNode.insertBefore(j, f);
        })(window, document, 'script', 'dataLayer', 'GTM-KHDP6Z');</script>
    <!-- End Google Tag Manager -->


    <!-- AHRQ HEADER -->
<div id="ahrq-header">

	<p class="hhs-links">
		<a href="https://web.archive.org/web/20180712210624/http://www.hhs.gov/" target="_blank" class="logo-hhs"><span class="logomark"></span>U.S.&nbsp;Department of&nbsp;Health&nbsp;and Human&nbsp;Services</a>
		<a href="https://web.archive.org/web/20180712210624/http://www.hhs.gov/" target="_blank" class="external-link"><strong>HHS.gov</strong></a>
	</p><!-- /.hhs-links -->
	<p class="ahrq-links">
		<a href="https://web.archive.org/web/20180712210624/http://www.ahrq.gov/" target="_blank" class="logo-ahrq">Agency for Healthcare Research and Quality: Advancing Excellence in Health Care</a>
		<a href="https://web.archive.org/web/20180712210624/http://www.ahrq.gov/" target="_blank" class="external-link"><strong>AHRQ.gov</strong></a>
	</p><!-- /.ahrq-links -->

</div><!-- /#ahrq-header -->

	<!-- HEADER -->
	<div class="header" id="header">
		<div class="masthead">

			<ul class="header-actions">
				<li><a href="#header-search" class="search-action"><span class="label">Search</span></a></li>
				<li><a href="#header-account" class="account-action"><span class="label">Account</span></a></li>
				<li><a href="#main-nav" class="menu-action"><span class="label">Menu</span></a></li>
			</ul><!-- /.header-actions -->
				
				<a href="/web/20180712210624/https://www.guideline.gov/" class="header-logo NGC">
				    <picture>
				        <source media="(min-width: 960px)" srcset="/web/20180712210624im_/https://www.guideline.gov/UI/images/logo_NGC_header.png">
				        <source srcset="/web/20180712210624im_/https://www.guideline.gov/UI/images/logo_NGC_header_m.png">
				        <img src="/web/20180712210624im_/https://www.guideline.gov/UI/images/logo_NGC_header.png" alt="National Guideline Clearinghouse">
				    </picture>
				</a>
<form action="/web/20180712210624/https://www.guideline.gov/search" class="header-search header-action" enctype="multipart/form-data" id="header-search" method="get">					<p class="search-bar">
						<label for="q"><span class="screen-reader-text">Search</span>
							<input id="q" type="text" title="Search Input" name="q" class="search-input" placeholder="Search">
						</label>
						<input id="masthead-search-button" type="submit" title="Search Submit" class="search-submit" value="Search">
					</p>
					<p class="search-tips">
						<a href="/web/20180712210624/https://www.guideline.gov/help-and-about/search-browse/search-tips">Search Tips</a>
					</p>
</form>				<div class="header-account header-action" id="header-account">
				<a id="login-button" class="signin" href="/web/20180712210624/https://www.guideline.gov/accounts/signinlanding" aria-role="tab" aria-controls="login-panel" aria-selected="false">Log into My NGC</a>
<div id="login-panel" class="login dropdown" aria-role="tab-panel" aria-labeledby="login-button" aria-hidden="true">
    
            <div class="sign-in">
            <form id="sign-in-form" action="/web/20180712210624/https://www.guideline.gov/Accounts/LoginSubmit" method="post">
                <h3>Sign In</h3>
                <div class="errormessages"></div>
                <p class="invalid-user-cred message-block" style="display: none;"></p>
                <p>
                    <label for="sign-in-username">Username or Email <span class="required">*</span></label>
                    <input type="text" id="sign-in-username" class="input-text" name="email" required>
                   
                </p>
                <p>
                    <label for="sign-in-userpwd">Password <span class="required">*</span></label>
                    <input type="password" id="sign-in-userpwd" class="input-text" name="password" required>
                  
                </p>
                <p class="form-link"><a href="/web/20180712210624/https://www.guideline.gov/accounts/forgotpassword">Forgot Password?</a></p>
                <p><label for="remember-me"><input type="checkbox" name="remember-me" id="remember-me">Remember Me</label></p>
                <input id="account-sign-in" type="submit" value="Sign In"/>
            </form>
            <p>
                <label for="sign-up-btn">Don't have an account?</label>
                <a href="/web/20180712210624/https://www.guideline.gov/accounts/login" class="sign-up-btn" id="sign-up-btn">Create New Account</a>
            </p>
        </div><!--/.sign-in-->
</div><!-- /.login -->
				</div><!-- /.header-account -->
		</div><!-- /.masthead -->

		<div class="main-nav header-action" id="main-nav">
		    <ul class="level-1">
		        <li class=""><a href="/web/20180712210624/https://www.guideline.gov/">Home</a></li>
		        <li class=""><a href="/web/20180712210624/https://www.guideline.gov/new-this-week/index">New This Week</a></li>
		        <li>
<a href="/web/20180712210624/https://www.guideline.gov/summaries/browse" class="parent-link">Guideline Summaries</a>                    		            <ul class="level-2 dropdown">
                             <li class=""><a href="/web/20180712210624/https://www.guideline.gov/browse/clinical-specialty">By Clinical Specialty</a></li>
		                <li class=""><a href="/web/20180712210624/https://www.guideline.gov/browse/organization">By Organization</a></li>
		                <li class=""><a href="/web/20180712210624/https://www.guideline.gov/browse/mesh-tag">By MeSH Tag</a></li>
		                <li class=""><a href="/web/20180712210624/https://www.guideline.gov/summaries/in-progress">In Progress</a></li>
		                <li class=""><a href="/web/20180712210624/https://www.guideline.gov/summaries/archive">Archive</a></li>

		                <li class=""><a href="/web/20180712210624/https://www.guideline.gov/search?f_DocType=0&amp;fLockTerm=Guideline Summaries">All Summaries</a></li>
		            </ul>
		        </li>
<li class=""><a href="/web/20180712210624/https://www.guideline.gov/syntheses/index">Guideline Syntheses</a></li>		        <li class=""><a href="/web/20180712210624/https://www.guideline.gov/expert">Expert Commentaries</a></li>
		        <li class=""><a href="/web/20180712210624/https://www.guideline.gov/matrix">Matrix Tool</a></li>
		        <li class="">
<a href="/web/20180712210624/https://www.guideline.gov/summaries/submit">Submit Guidelines</a>                    		        </li>
                <li class=""><a href="/web/20180712210624/https://www.guideline.gov/help-and-about">Help &amp;&nbsp;About</a></li>		      
		    </ul>
		</div><!-- /.main-nav -->
</div><!-- /.header -->

    <br/><div class="content"><div class="fundingNotice2"><b>The AHRQ National Guideline Clearinghouse (NGC, guideline.gov) Web site will not be available after July 16, 2018</b> because federal funding <br/>through AHRQ will no longer be available to support the NGC as of that date. For additional information, read our <a href="/web/20180712210624/https://www.guideline.gov/home/announcements">full announcement</a>.</div></div>

	<!-- CONTENT -->
	<main id="main-content" tabindex="-1">
		

<div class="main">

		<div class="aside-container">

	<div class="content">

    <!-- CONTENT HEADER -->
    <div class="content-header">
        <ul class="content-header-meta">
            <li class="prefix-icon guideline">Guideline Summary</li>
            <li>NGC:010385</li>
            <li>2013 Apr
            </li>            
                                </ul>
        <div>
                <h1>Upper tract urothelial tumours.</h1>
        </div>
    </div>
    <!-- /.content-header-meta -->

        <!-- CONTENT TABS -->
        <ul class="content-tabs">
            <li><a href="#developer-tab" class="developer is-active"><span class="label">Developer</span></a></li>
            <li><a href="#source-tab" class="source"><span class="label">Source</span></a></li>
            <li><a href="#status-tab" class="status"><span class="label">Status</span></a></li>
            <li><a href="#classification-tab" class="classification"><span class="label">Classification</span></a></li>
        </ul>
        <div id="developer-tab" class="is-active content-tab-panel">
                <ul class="developer-list">
        <li><a href="/web/20180712210624/https://www.guideline.gov/search?f_Guideline_Developer_String=CancerControl%20Alberta&amp;fLockTerm=CancerControl%2BAlberta">CancerControl Alberta</a></li>
                        <li>   
                                <a id="2278" href="#" data-alert="SignInLanding" data-alert-type="organization" class="get-alerts get-org-alerts">Get Alerts</a>
                        </li>
                </ul>
        </div>
    <!-- /.content-tab-panel -->
    <div id="source-tab" class="content-tab-panel">
<table><tr><td>Alberta Provincial Genitourinary Tumour Team. Upper tract urothelial tumours. Edmonton (Alberta): CancerControl Alberta; 2013 Apr. 10 p.&nbsp;(Clinical practice guideline; no. GU-008).&nbsp; [22 references]</td></tr></table>                    <p><a href="/web/20180712210624/https://www.guideline.gov/Home/Disclaimer?id=48139&amp;contentType=fulltextlink&amp;redirect=http%253a%252f%252fwww.albertahealthservices.ca%252fassets%252finfo%252fhp%252fcancer%252fif-hp-cancer-guide-gu008-upper-tract.pdf">View the original guideline documentation</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180712210624im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/></p>
    </div>
    <!-- /.content-tab-panel -->
    <div id="status-tab" class="content-tab-panel">
            <p><div class="content_para"><p>This is the current release of the guideline.</p></div></p>
    </div>
    <!-- /.content-tab-panel -->
    <div id="classification-tab" class="content-tab-panel">


        
                    <h4>Age Group</h4>
            <ul>
                        <li><a href="/web/20180712210624/https://www.guideline.gov/search?f_Age_of_Target_Population=Middle%20Age%20%2845%20to%2064%20years%29&amp;fLockTerm=Middle%2BAge%2B%2845%2Bto%2B64%2Byears%29">Middle Age (45 to 64 years)</a></li>                      
                        <li><a href="/web/20180712210624/https://www.guideline.gov/search?f_Age_of_Target_Population=Aged%2C%2080%20and%20over&amp;fLockTerm=Aged%252c%2B80%2Band%2Bover">Aged, 80 and over</a></li>                      
                        <li><a href="/web/20180712210624/https://www.guideline.gov/search?f_Age_of_Target_Population=Aged%20%2865%20to%2079%20years%29&amp;fLockTerm=Aged%2B%2865%2Bto%2B79%2Byears%29">Aged (65 to 79 years)</a></li>                      
                        <li><a href="/web/20180712210624/https://www.guideline.gov/search?f_Age_of_Target_Population=Adult%20%2819%20to%2044%20years%29&amp;fLockTerm=Adult%2B%2819%2Bto%2B44%2Byears%29">Adult (19 to 44 years)</a></li>                      
            </ul>
                    <h4>UMLS Concepts <a href="/web/20180712210624/https://www.guideline.gov/help-and-about/search-browse/umls-concepts" class="what-is">(what is this?)</a></h4>
                <div class="field">
                    <h5 class="field-label">ICD9CM</h5>
                    <div class="field-content">
<a href="/web/20180712210624/https://www.guideline.gov/search?f_ICD9CM_CUI=C0203668&amp;fLockTerm=Bone+scan">Bone scan</a>
 (92.14), <a href="/web/20180712210624/https://www.guideline.gov/search?f_ICD9CM_CUI=C0154092&amp;fLockTerm=Carcinoma+in+situ+of+other+and+unspecified+urinary+organs">Carcinoma in situ of other and unspecified urinary organs</a>
 (233.9), <a href="/web/20180712210624/https://www.guideline.gov/search?f_ICD9CM_CUI=C0203108&amp;fLockTerm=Intravenous+pyelogram">Intravenous pyelogram</a>
 (87.73), <a href="/web/20180712210624/https://www.guideline.gov/search?f_ICD9CM_CUI=C0153618&amp;fLockTerm=Malignant+neoplasm+of+renal+pelvis">Malignant neoplasm of renal pelvis</a>
 (189.1), <a href="/web/20180712210624/https://www.guideline.gov/search?f_ICD9CM_CUI=C0153619&amp;fLockTerm=Malignant+neoplasm+of+ureter">Malignant neoplasm of ureter</a>
 (189.2), <a href="/web/20180712210624/https://www.guideline.gov/search?f_ICD9CM_CUI=C0027732&amp;fLockTerm=Nephroureterectomy">Nephroureterectomy</a>
 (55.51), <a href="/web/20180712210624/https://www.guideline.gov/search?f_ICD9CM_CUI=C0203110&amp;fLockTerm=Retrograde+pyelogram">Retrograde pyelogram</a>
 (87.74), <a href="/web/20180712210624/https://www.guideline.gov/search?f_ICD9CM_CUI=C0194224&amp;fLockTerm=Ureterectomy%2c+not+otherwise+specified">Ureterectomy, not otherwise specified</a>
 (56.40), <a href="/web/20180712210624/https://www.guideline.gov/search?f_ICD9CM_CUI=C0194261&amp;fLockTerm=Ureteroscopy">Ureteroscopy</a>
 (56.31)                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">MSH</h5>
                    <div class="field-content">
<a href="/web/20180712210624/https://www.guideline.gov/search?f_MSH_CUI=C0005771&amp;fLockTerm=Blood+Cell+Count">Blood Cell Count</a>
, <a href="/web/20180712210624/https://www.guideline.gov/search?f_MSH_CUI=C0007138&amp;fLockTerm=Carcinoma%2c+Transitional+Cell">Carcinoma, Transitional Cell</a>
, <a href="/web/20180712210624/https://www.guideline.gov/search?f_MSH_CUI=C0085533&amp;fLockTerm=Chemotherapy%2c+Adjuvant">Chemotherapy, Adjuvant</a>
, <a href="/web/20180712210624/https://www.guideline.gov/search?f_MSH_CUI=C0008838&amp;fLockTerm=Cisplatin">Cisplatin</a>
, <a href="/web/20180712210624/https://www.guideline.gov/search?f_MSH_CUI=C0180274&amp;fLockTerm=Cystoscopes">Cystoscopes</a>
, <a href="/web/20180712210624/https://www.guideline.gov/search?f_MSH_CUI=C0010702&amp;fLockTerm=Cystoscopy">Cystoscopy</a>
, <a href="/web/20180712210624/https://www.guideline.gov/search?f_MSH_CUI=C0010818&amp;fLockTerm=Cytological+Techniques">Cytological Techniques</a>
, <a href="/web/20180712210624/https://www.guideline.gov/search?f_MSH_CUI=C0014243&amp;fLockTerm=Endoscopes">Endoscopes</a>
, <a href="/web/20180712210624/https://www.guideline.gov/search?f_MSH_CUI=C0014245&amp;fLockTerm=Endoscopy">Endoscopy</a>
, <a href="/web/20180712210624/https://www.guideline.gov/search?f_MSH_CUI=C0022662&amp;fLockTerm=Kidney+Function+Tests">Kidney Function Tests</a>
, <a href="/web/20180712210624/https://www.guideline.gov/search?f_MSH_CUI=C0024485&amp;fLockTerm=Magnetic+Resonance+Imaging">Magnetic Resonance Imaging</a>
, <a href="/web/20180712210624/https://www.guideline.gov/search?f_MSH_CUI=C0600558&amp;fLockTerm=Neoadjuvant+Therapy">Neoadjuvant Therapy</a>
, <a href="/web/20180712210624/https://www.guideline.gov/search?f_MSH_CUI=C0027732&amp;fLockTerm=Nephroureterectomy">Nephroureterectomy</a>
, <a href="/web/20180712210624/https://www.guideline.gov/search?f_MSH_CUI=C3178790&amp;fLockTerm=Organ+Sparing+Treatments">Organ Sparing Treatments</a>
, <a href="/web/20180712210624/https://www.guideline.gov/search?f_MSH_CUI=C0030793&amp;fLockTerm=Pelvic+Neoplasms">Pelvic Neoplasms</a>
, <a href="/web/20180712210624/https://www.guideline.gov/search?f_MSH_CUI=C0034606&amp;fLockTerm=Radionuclide+Imaging">Radionuclide Imaging</a>
, <a href="/web/20180712210624/https://www.guideline.gov/search?f_MSH_CUI=C0936234&amp;fLockTerm=Tomography+Scanners%2c+X-Ray+Computed">Tomography Scanners, X-Ray Computed</a>
, <a href="/web/20180712210624/https://www.guideline.gov/search?f_MSH_CUI=C0040405&amp;fLockTerm=Tomography%2c+X-Ray+Computed">Tomography, X-Ray Computed</a>
, <a href="/web/20180712210624/https://www.guideline.gov/search?f_MSH_CUI=C0041955&amp;fLockTerm=Ureteral+Neoplasms">Ureteral Neoplasms</a>
, <a href="/web/20180712210624/https://www.guideline.gov/search?f_MSH_CUI=C0184213&amp;fLockTerm=Ureteroscopes">Ureteroscopes</a>
, <a href="/web/20180712210624/https://www.guideline.gov/search?f_MSH_CUI=C0194261&amp;fLockTerm=Ureteroscopy">Ureteroscopy</a>
, <a href="/web/20180712210624/https://www.guideline.gov/search?f_MSH_CUI=C0042070&amp;fLockTerm=Urography">Urography</a>
, <a href="/web/20180712210624/https://www.guideline.gov/search?f_MSH_CUI=C0042076&amp;fLockTerm=Urologic+Neoplasms">Urologic Neoplasms</a>
, <a href="/web/20180712210624/https://www.guideline.gov/search?f_MSH_CUI=C0038913&amp;fLockTerm=Urologic+Surgical+Procedures">Urologic Surgical Procedures</a>
                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">MTH</h5>
                    <div class="field-content">
<a href="/web/20180712210624/https://www.guideline.gov/search?f_MTH_CUI=C0005771&amp;fLockTerm=blood+cell+count">blood cell count</a>
, <a href="/web/20180712210624/https://www.guideline.gov/search?f_MTH_CUI=C0007138&amp;fLockTerm=Carcinoma%2c+Transitional+Cell">Carcinoma, Transitional Cell</a>
, <a href="/web/20180712210624/https://www.guideline.gov/search?f_MTH_CUI=C0008838&amp;fLockTerm=Cisplatin">Cisplatin</a>
, <a href="/web/20180712210624/https://www.guideline.gov/search?f_MTH_CUI=C0936234&amp;fLockTerm=Computed+Tomography+Scanning+Systems">Computed Tomography Scanning Systems</a>
, <a href="/web/20180712210624/https://www.guideline.gov/search?f_MTH_CUI=C0010702&amp;fLockTerm=Cystoscopy">Cystoscopy</a>
, <a href="/web/20180712210624/https://www.guideline.gov/search?f_MTH_CUI=C0010818&amp;fLockTerm=Cytological+Techniques">Cytological Techniques</a>
, <a href="/web/20180712210624/https://www.guideline.gov/search?f_MTH_CUI=C0014243&amp;fLockTerm=Endoscopes">Endoscopes</a>
, <a href="/web/20180712210624/https://www.guideline.gov/search?f_MTH_CUI=C0014245&amp;fLockTerm=Endoscopy+(procedure)">Endoscopy (procedure)</a>
, <a href="/web/20180712210624/https://www.guideline.gov/search?f_MTH_CUI=C0587953&amp;fLockTerm=Finding+of+urine+cytology">Finding of urine cytology</a>
, <a href="/web/20180712210624/https://www.guideline.gov/search?f_MTH_CUI=C1522577&amp;fLockTerm=follow-up">follow-up</a>
, <a href="/web/20180712210624/https://www.guideline.gov/search?f_MTH_CUI=C0589120&amp;fLockTerm=Follow-up+status">Follow-up status</a>
, <a href="/web/20180712210624/https://www.guideline.gov/search?f_MTH_CUI=C0203108&amp;fLockTerm=Intravenous+pyelogram">Intravenous pyelogram</a>
, <a href="/web/20180712210624/https://www.guideline.gov/search?f_MTH_CUI=C0022662&amp;fLockTerm=Kidney+Function+Tests">Kidney Function Tests</a>
, <a href="/web/20180712210624/https://www.guideline.gov/search?f_MTH_CUI=C0024485&amp;fLockTerm=Magnetic+Resonance+Imaging">Magnetic Resonance Imaging</a>
, <a href="/web/20180712210624/https://www.guideline.gov/search?f_MTH_CUI=C3164721&amp;fLockTerm=Malignant+epithelial+neoplasm+of+ureter">Malignant epithelial neoplasm of ureter</a>
, <a href="/web/20180712210624/https://www.guideline.gov/search?f_MTH_CUI=C0153619&amp;fLockTerm=Malignant+neoplasm+of+ureter">Malignant neoplasm of ureter</a>
, <a href="/web/20180712210624/https://www.guideline.gov/search?f_MTH_CUI=C0030793&amp;fLockTerm=Pelvic+Neoplasms">Pelvic Neoplasms</a>
, <a href="/web/20180712210624/https://www.guideline.gov/search?f_MTH_CUI=C0039985&amp;fLockTerm=Plain+chest+X-ray">Plain chest X-ray</a>
, <a href="/web/20180712210624/https://www.guideline.gov/search?f_MTH_CUI=C0203668&amp;fLockTerm=Radioisotope+scan+of+bone">Radioisotope scan of bone</a>
, <a href="/web/20180712210624/https://www.guideline.gov/search?f_MTH_CUI=C0034606&amp;fLockTerm=Radionuclide+Imaging">Radionuclide Imaging</a>
, <a href="/web/20180712210624/https://www.guideline.gov/search?f_MTH_CUI=C0203110&amp;fLockTerm=Retrograde+pyelogram">Retrograde pyelogram</a>
, <a href="/web/20180712210624/https://www.guideline.gov/search?f_MTH_CUI=C0184213&amp;fLockTerm=Ureteroscopes">Ureteroscopes</a>
, <a href="/web/20180712210624/https://www.guideline.gov/search?f_MTH_CUI=C0194261&amp;fLockTerm=Ureteroscopy">Ureteroscopy</a>
, <a href="/web/20180712210624/https://www.guideline.gov/search?f_MTH_CUI=C0042070&amp;fLockTerm=Urography">Urography</a>
, <a href="/web/20180712210624/https://www.guideline.gov/search?f_MTH_CUI=C0042076&amp;fLockTerm=Urologic+Neoplasms">Urologic Neoplasms</a>
, <a href="/web/20180712210624/https://www.guideline.gov/search?f_MTH_CUI=C0040405&amp;fLockTerm=X-Ray+Computed+Tomography">X-Ray Computed Tomography</a>
                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">PDQ</h5>
                    <div class="field-content">
<a href="/web/20180712210624/https://www.guideline.gov/search?f_PDQ_CUI=C0008838&amp;fLockTerm=cisplatin">cisplatin</a>
, <a href="/web/20180712210624/https://www.guideline.gov/search?f_PDQ_CUI=C0040405&amp;fLockTerm=computed+tomography">computed tomography</a>
, <a href="/web/20180712210624/https://www.guideline.gov/search?f_PDQ_CUI=C0010702&amp;fLockTerm=cystoscopy">cystoscopy</a>
, <a href="/web/20180712210624/https://www.guideline.gov/search?f_PDQ_CUI=C0014245&amp;fLockTerm=endoscopy">endoscopy</a>
, <a href="/web/20180712210624/https://www.guideline.gov/search?f_PDQ_CUI=C0024485&amp;fLockTerm=magnetic+resonance+imaging">magnetic resonance imaging</a>
, <a href="/web/20180712210624/https://www.guideline.gov/search?f_PDQ_CUI=C0600558&amp;fLockTerm=neoadjuvant+therapy">neoadjuvant therapy</a>
, <a href="/web/20180712210624/https://www.guideline.gov/search?f_PDQ_CUI=C0034606&amp;fLockTerm=radionuclide+imaging">radionuclide imaging</a>
                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">SNOMEDCT_US</h5>
                    <div class="field-content">
<a href="/web/20180712210624/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0005771&amp;fLockTerm=Blood+cell+count">Blood cell count</a>
 (88308000), <a href="/web/20180712210624/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C3164721&amp;fLockTerm=Carcinoma+of+ureter">Carcinoma of ureter</a>
 (448864006), <a href="/web/20180712210624/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0008838&amp;fLockTerm=Cisplatin">Cisplatin</a>
 (387318005), <a href="/web/20180712210624/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0008838&amp;fLockTerm=Cisplatin">Cisplatin</a>
 (57066004), <a href="/web/20180712210624/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0040405&amp;fLockTerm=Computerized+axial+tomography">Computerized axial tomography</a>
 (77477000), <a href="/web/20180712210624/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0180274&amp;fLockTerm=Cystoscope">Cystoscope</a>
 (20613002), <a href="/web/20180712210624/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0010702&amp;fLockTerm=Cystoscopy">Cystoscopy</a>
 (24139008), <a href="/web/20180712210624/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0014243&amp;fLockTerm=Endoscope">Endoscope</a>
 (37270008), <a href="/web/20180712210624/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0014245&amp;fLockTerm=Endoscopy">Endoscopy</a>
 (423827005), <a href="/web/20180712210624/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0589120&amp;fLockTerm=Follow-up+status">Follow-up status</a>
 (308273005), <a href="/web/20180712210624/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0203108&amp;fLockTerm=Intravenous+pyelogram">Intravenous pyelogram</a>
 (32265006), <a href="/web/20180712210624/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0024485&amp;fLockTerm=Magnetic+resonance+imaging">Magnetic resonance imaging</a>
 (113091000), <a href="/web/20180712210624/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0024485&amp;fLockTerm=Magnetic+resonance+imaging">Magnetic resonance imaging</a>
 (312250003), <a href="/web/20180712210624/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0336660&amp;fLockTerm=Magnetic+resonance+imaging+unit">Magnetic resonance imaging unit</a>
 (90003000), <a href="/web/20180712210624/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0153618&amp;fLockTerm=Malignant+tumor+of+renal+pelvis">Malignant tumor of renal pelvis</a>
 (363457009), <a href="/web/20180712210624/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0153619&amp;fLockTerm=Malignant+tumor+of+ureter">Malignant tumor of ureter</a>
 (363458004), <a href="/web/20180712210624/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0030793&amp;fLockTerm=Neoplasm+of+pelvis">Neoplasm of pelvis</a>
 (126644004), <a href="/web/20180712210624/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0041955&amp;fLockTerm=Neoplasm+of+ureter">Neoplasm of ureter</a>
 (126882009), <a href="/web/20180712210624/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0042076&amp;fLockTerm=Neoplasm+of+urinary+system">Neoplasm of urinary system</a>
 (126879004), <a href="/web/20180712210624/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0042076&amp;fLockTerm=Neoplasm+of+urinary+system">Neoplasm of urinary system</a>
 (254913005), <a href="/web/20180712210624/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0027732&amp;fLockTerm=Nephroureterectomy">Nephroureterectomy</a>
 (175907006), <a href="/web/20180712210624/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0034606&amp;fLockTerm=Nuclear+medicine+imaging+procedure">Nuclear medicine imaging procedure</a>
 (373205008), <a href="/web/20180712210624/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0039985&amp;fLockTerm=Plain+chest+X-ray">Plain chest X-ray</a>
 (399208008), <a href="/web/20180712210624/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0203668&amp;fLockTerm=Radioisotope+scan+of+bone">Radioisotope scan of bone</a>
 (41747008), <a href="/web/20180712210624/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0022662&amp;fLockTerm=Renal+function+study">Renal function study</a>
 (44277000), <a href="/web/20180712210624/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0203110&amp;fLockTerm=Retrograde+pyelogram">Retrograde pyelogram</a>
 (405250000), <a href="/web/20180712210624/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0007138&amp;fLockTerm=Transitional+cell+carcinoma">Transitional cell carcinoma</a>
 (27090000), <a href="/web/20180712210624/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0194224&amp;fLockTerm=Ureterectomy">Ureterectomy</a>
 (108028005), <a href="/web/20180712210624/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0184213&amp;fLockTerm=Ureteroscope">Ureteroscope</a>
 (310801006), <a href="/web/20180712210624/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0194261&amp;fLockTerm=Ureteroscopy">Ureteroscopy</a>
 (387717002), <a href="/web/20180712210624/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0194305&amp;fLockTerm=Ureteroureterostomy">Ureteroureterostomy</a>
 (176028006), <a href="/web/20180712210624/https://www.guideline.gov/search?f_SNOMEDCT_US_CUI=C0587953&amp;fLockTerm=Urine+cytology">Urine cytology</a>
 (310437009)                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">SPN</h5>
                    <div class="field-content">
<a href="/web/20180712210624/https://www.guideline.gov/search?f_SPN_CUI=C0014243&amp;fLockTerm=ENDOSCOPE+AND%2fOR+ACCESSORIES">ENDOSCOPE AND/OR ACCESSORIES</a>
, <a href="/web/20180712210624/https://www.guideline.gov/search?f_SPN_CUI=C0336660&amp;fLockTerm=SYSTEM%2c+NUCLEAR+MAGNETIC+RESONANCE+IMAGING">SYSTEM, NUCLEAR MAGNETIC RESONANCE IMAGING</a>
, <a href="/web/20180712210624/https://www.guideline.gov/search?f_SPN_CUI=C0936234&amp;fLockTerm=SYSTEM%2c+X-RAY%2c+TOMOGRAPHY%2c+COMPUTED">SYSTEM, X-RAY, TOMOGRAPHY, COMPUTED</a>
, <a href="/web/20180712210624/https://www.guideline.gov/search?f_SPN_CUI=C0184213&amp;fLockTerm=URETEROSCOPE">URETEROSCOPE</a>
                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
                <div class="field">
                    <h5 class="field-label">UMD</h5>
                    <div class="field-content">
<a href="/web/20180712210624/https://www.guideline.gov/search?f_UMD_CUI=C0180274&amp;fLockTerm=Cystoscopes">Cystoscopes</a>
 (11-112), <a href="/web/20180712210624/https://www.guideline.gov/search?f_UMD_CUI=C0014243&amp;fLockTerm=Endoscopes">Endoscopes</a>
 (20-475), <a href="/web/20180712210624/https://www.guideline.gov/search?f_UMD_CUI=C0182606&amp;fLockTerm=Radiographic+Units%2c+Chest">Radiographic Units, Chest</a>
 (10-822), <a href="/web/20180712210624/https://www.guideline.gov/search?f_UMD_CUI=C0936234&amp;fLockTerm=Scanning+Systems%2c+Computed+Tomography">Scanning Systems, Computed Tomography</a>
 (13-469), <a href="/web/20180712210624/https://www.guideline.gov/search?f_UMD_CUI=C0336660&amp;fLockTerm=Scanning+Systems%2c+Magnetic+Resonance+Imaging">Scanning Systems, Magnetic Resonance Imaging</a>
 (16-260), <a href="/web/20180712210624/https://www.guideline.gov/search?f_UMD_CUI=C0184213&amp;fLockTerm=Ureteroscopes">Ureteroscopes</a>
 (15-788)                    </div>
                    <!-- /.field-content -->
                </div>
                <!-- /.field -->
    </div>
        <!-- /.content-tab-panel -->
        <!-- /.content-tab-panel -->
        <!-- TOOLBAR -->
        <div class="content-toolbar">

            <!-- Primary -->
            <ul class="tools primary-tools">
                <li class="dropdown tool sections">
                    <a href="#" class="tool-button">Sections</a>
                    <div class="dropdown-panel">
                            <ul class="section-links">
                                    <li><a href="#420" class="section-mark">Recommendations</a></li>
                                    <li><a href="#396" class="section-mark">Scope</a></li>
                                    <li><a href="#405" class="section-mark">Methodology</a></li>
                                    <li><a href="#424" class="section-mark">Evidence Supporting the Recommendations</a></li>
                                    <li><a href="#427" class="section-mark">Benefits/Harms of Implementing the Guideline Recommendations</a></li>
                                    <li><a href="#432" class="section-mark">Qualifying Statements</a></li>
                                    <li><a href="#434" class="section-mark">Implementation of the Guideline</a></li>
                                    <li><a href="#439" class="section-mark">Institute of Medicine (IOM) National Healthcare Quality Report Categories</a></li>
                                    <li><a href="#442" class="section-mark">Identifying Information and Availability</a></li>
                                    <li><a href="#99999" class="section-mark">Disclaimer</a></li>
                            </ul>    
                    </div>
                    <!-- /.dropdown-panel -->
                </li>
            </ul>

            <!-- Other -->
            <ul class="tools other-tools">
                <li class="dropdown tool">
                    <a href="#" class="tool-button">Download</a>

                    <div class="dropdown-panel">
                        <ul>
                            <li><a href="/web/20180712210624/https://www.guideline.gov/summaries/downloadcontent/ngc-10385?contentType=pdf" class="pdf">.PDF 81.2 kb</a></li>
                            <li><a href="/web/20180712210624/https://www.guideline.gov/summaries/downloadcontent/ngc-10385?contentType=word" class="word">Word Document 280.8 kb</a></li>
                            <li><a href="/web/20180712210624/https://www.guideline.gov/summaries/downloadcontent/ngc-10385?contentType=xml" class="xml">.XML 31.7 kb</a></li>
                        </ul>
                    </div>
                    <!-- /.dropdown-panel -->
                </li>
                <li class="dropdown tool">
                    <a href="#" class="tool-button">Share</a>
                    <div class="dropdown-panel">
                        <ul class="toolbar-social">
                            <li><a target="_blank" href="https://web.archive.org/web/20180712210624/https://www.facebook.com/sharer/sharer.php?u=https://www.guideline.gov/summaries/summary/48139/upper-tract-urothelial-tumours" class="facebook">Facebook</a></li>
                            <li><a target="_blank" href="https://web.archive.org/web/20180712210624/https://twitter.com/share?text=&amp;url=https://www.guideline.gov/summaries/summary/48139/upper-tract-urothelial-tumours" class="twitter">Twitter</a></li>
                            <li><a target="_blank" href="https://web.archive.org/web/20180712210624/https://www.linkedin.com/shareArticle?mini=true&amp;url=https://www.guideline.gov/summaries/summary/48139/upper-tract-urothelial-tumours&amp;title=&amp;summary=&amp;source=" class="linkedin">Linkedin</a></li>
                            <li><a href="https://web.archive.org/web/20180712210624/mailto:/?Subject=AHRQ: Upper tract urothelial tumours.&amp;body=https://www.guideline.gov/summaries/summary/48139/upper-tract-urothelial-tumours" class="email">Email</a></li>
                        </ul>
                    </div>
                    <!-- /.dropdown-panel -->
                </li>
                <li class="dropdown tool">
                    <a href="#" class="tool-button">Cite</a>
                    <div class="dropdown-panel citation">
                        <p class="text-label"><label for="citation">Citation: </label></p>
                        <textarea id="citation">National Guideline Clearinghouse (NGC). Guideline summary: Upper tract urothelial tumours. In: National Guideline Clearinghouse (NGC) [Web site]. Rockville (MD): Agency for Healthcare Research and Quality (AHRQ); 2013 Apr 01. [cited 2018 Jul 12]. Available: https://www.guideline.gov</textarea>                        
                        <p class="text-label">Download citation file: </p>
                        <ul>
                            <li><a href="/web/20180712210624/https://www.guideline.gov/summaries/citedownload/48139?format=ris">RIS (Zotero)</a></li>
                            <li><a href="/web/20180712210624/https://www.guideline.gov/summaries/citedownload/48139?format=enw">EndNote</a></li>
                            <li><a href="/web/20180712210624/https://www.guideline.gov/summaries/citedownload/48139?format=bibtex">BibTex</a></li>
                            <li><a href="/web/20180712210624/https://www.guideline.gov/summaries/citedownload/48139?format=txt">Medlars</a></li>
                            <li><a href="/web/20180712210624/https://www.guideline.gov/summaries/citedownload/48139?format=ris">ProCite</a></li>
                            <li><a href="/web/20180712210624/https://www.guideline.gov/summaries/citedownload/48139">RefWorks</a></li>
                            <li><a href="/web/20180712210624/https://www.guideline.gov/summaries/citedownload/48139?format=ris">Reference Manager</a></li>
                        </ul>
                    </div>
                    <!-- /.dropdown-panel -->
                </li>
                                
                <li class="tool">
                        <a href="#" id="48139" data-alert="SignInLanding" class="tool-button save-link">Save</a>
                </li>
            </ul>

            <!-- Accordion -->
            <ul class="tools accordion-controls">
                <li class="tool"><a href="#" class="expand-all is-disabled" aria-disabled="true"><span class="screen-reader-text">Expand All</span></a></li>
                <li class="tool"><a href="#" class="collapse-all" aria-disabled="false"><span class="screen-reader-text">Collapse All</span></a></li>
            </ul>
        </div>
        <!-- /.toolbar -->


		<!-- ARTICLE -->
		<div class="article" id="article">
			




    <!-- ACCORDION -->
    <div class="accordion-container" role="tablist" multiselectable="true">
                <h2 id="420" class="accordion-title section-420 is-active" role="tab" aria-expanded="true"><a href="#">Recommendations</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Major Recommendations</a></h3>
                    <p><div class="content_para"><p><strong><span style="text-decoration: underline;">Work-up</span></strong></p>
<p><strong>Laboratory Investigations</strong></p>
<ul style="list-style-type: disc;">
    <li>Urine cytology </li>
    <li>Complete blood count </li>
    <li>Basic metabolic panel (renal function) </li>
</ul>
<p><strong>Imaging Studies</strong></p>
<ul style="list-style-type: disc;">
    <li>Intravenous pyelogram (IVP), computed tomography (CT) urography, retrograde pyelogram, ureteroscopy, or magnetic resonance imaging (MRI) urogram (upper tract collecting system) </li>
    <li>Cystoscopy </li>
    <li>Chest x-ray </li>
    <li>Renal scan (optional) </li>
    <li>Bone scan if abnormal enzymes or if bone signs/symptoms </li>
</ul>
<p><strong><span style="text-decoration: underline;">Treatment</span></strong></p>
<p><strong>Primary Therapy for the Renal Pelvis</strong></p>
<p><em>Low-Grade (World Health Organization [WHO] Classification)</em></p>
<ul style="list-style-type: disc;">
    <li>Nephroureterectomy with cuff of bladder or nephron-sparing procedure, if necessary, due to renal impairment and/or comorbidities </li>
</ul>
<p><em>High-Grade (WHO Classification) or Parenchymal Invasion</em></p>
<ul style="list-style-type: disc;">
    <li>Nephroureterectomy with cuff of bladder </li>
    <li>Regional lymph node dissection </li>
    <li>Neoadjuvant chemotherapy can be considered, if the degree of disease invasiveness can be established prior to surgery
    <ul style="list-style-type: disc;">
        <li>Chemotherapy is usually given as cisplatinum-based combination therapy (e.g., cisplatinum, 70 mg/m<sup>2</sup> day 1 and gemcitabine, 1,000&ndash;1,250 mg/m<sup>2</sup> day 1 and 8 every [q] 21 days). </li>
        <li>Neoadjuvant therapy should be given only when renal function is optimal. </li>
        <li>Patients with contraindications to cisplatinum should proceed directly to definitive therapy, as the routine use of carboplatinum-based neoadjuvant combinations cannot be advised. </li>
        <li>Following neoadjuvant chemotherapy patients should have a CT scan of abdomen and pelvis, prior to the cystectomy. </li>
    </ul>
    </li>
</ul>
<p><strong>Primary Therapy for the Urothelial Carcinoma of the Ureter</strong></p>
<p><em>Low-Grade (WHO Classification)</em></p>
<ul style="list-style-type: disc;">
    <li>Nephroureterectomy with cuff of bladder or nephron-sparing procedure, if necessary, due to renal impairment and/or comorbidities </li>
</ul>
<p><em>High-Grade (WHO Classification)</em></p>
<ul style="list-style-type: disc;">
    <li>Excision options:
    <ul style="list-style-type: disc;">
        <li>Nephroureterectomy with cuff of bladder </li>
        <li>Endoscopic resection </li>
        <li>Excision and ureteroureterostomy (low-grade mid-ureter) </li>
        <li>Distal ureterectomy (distal-ureter) </li>
    </ul>
    </li>
    <li>Regional lymph node dissection </li>
    <li>Neoadjuvant chemotherapy should be considered in selected patients with proven high-grade disease or imaging suggesting invasive disease.
    <ul style="list-style-type: disc;">
        <li>Chemotherapy is usually given as cisplatinum-based combination therapy (e.g., cisplatinum, 70 mg/m<sup>2</sup> day 1 and gemcitabine, 1000&ndash;1250 mg/m<sup>2</sup> day 1 and 8 q 21 days). </li>
        <li>Neoadjuvant therapy should be given only when renal function is optimal. </li>
        <li>Patients with contraindications to cisplatinum should proceed directly to definitive therapy, as the routine use of carboplatinum-based neoadjuvant combinations cannot be advised. </li>
        <li>Following neoadjuvant chemotherapy patients should have a CT scan of abdomen and pelvis, prior to the cystectomy. </li>
    </ul>
    </li>
</ul>
<p><strong>Primary Therapy for Metastatic Urothelial Carcinoma</strong></p>
<p>Chemotherapy is recommended for metastatic upper tract tumours. Please refer to the CancerControl Alberta guideline <a href="/web/20180712210624/https://www.guideline.gov/Home/Disclaimer?id=48139&amp;contentType=summary&amp;redirect=http%3a%2f%2fwww.albertahealthservices.ca%2fhp%2fif-hp-cancer-guide-gu002-bladder.pdf" title="Alberta Health Services Web site">Bladder Cancer</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180712210624im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/> (GU-002) for treatment options. </p>
<p><strong>Adjuvant Therapy</strong></p>
<p>The decision as to whether to give adjuvant therapy is based on the pathologic stage of disease. For staging, refer to the Appendix in the original guideline document.</p>
<p><em>pT0-1 Disease</em></p>
<ul style="list-style-type: disc;">
    <li>No adjuvant therapy is recommended. </li>
</ul>
<p><em>T2-4, N+ Disease</em></p>
<ul style="list-style-type: disc;">
    <li>Adjuvant chemotherapy can be considered.
    <ul style="list-style-type: disc;">
        <li>Chemotherapy is usually given as cisplatinum-based combination therapy (e.g., cisplatinum, 70 mg/m<sup>2</sup> day 1 and gemcitabine, 1000&ndash;1250 mg/m<sup>2</sup> day 1 and 8 q 21 days). </li>
        <li>Adjuvant therapy should be given when renal function is optimal. </li>
        <li>Patients who are ineligible for cisplatinum based combination therapy in the adjuvant setting should not routinely receive carboplatinum-based regimens as there is no evidence for benefit. </li>
    </ul>
    </li>
</ul>
<p><strong><span style="text-decoration: underline;">Follow-up</span></strong></p>
<ul style="list-style-type: disc;">
    <li>Cystoscopic evaluation every 3 months for the first year, then at every 6 months up to 2 years, then annually for 10 years. </li>
    <li>Chest x-ray as clinically indicated, then at increasing intervals (i.e., decreasing frequency). </li>
    <li>Radiological evaluation of lymph nodes and contra lateral upper tract, as clinically indicated. </li>
    <li>Duration as clinically indicated. </li>
</ul></div></p>
                        <h3><a href="#">Clinical Algorithm(s)</a></h3>
                    <p><div class="content_para"><p>None provided</p></div></p>

            </div>
                <h2 id="396" class="accordion-title section-396 is-active" role="tab" aria-expanded="true"><a href="#">Scope</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Disease/Condition(s)</a></h3>
                    <p><div class="content_para"><p>Upper tract urothelial tumours (transitional cell carcinoma of the ureter and/or renal pelvis)</p></div></p>
                        <h3><a href="#">Guideline Category</a></h3>
                    <p>Diagnosis</p>
                    <p>Evaluation</p>
                    <p>Management</p>
                    <p>Treatment</p>
                        <h3><a href="#">Clinical Specialty</a></h3>
                    <p>Oncology</p>
                    <p>Pathology</p>
                    <p>Radiology</p>
                    <p>Surgery</p>
                    <p>Urology</p>
                        <h3><a href="#">Intended Users</a></h3>
                    <p>Advanced Practice Nurses</p>
                    <p>Nurses</p>
                    <p>Physician Assistants</p>
                    <p>Physicians</p>
                        <h3><a href="#">Guideline Objective(s)</a></h3>
                    <p><div class="content_para"><p>To present guideline recommendations on the management of adult patients with transitional cell carcinoma (urothelial carcinoma) of the ureter and/or renal pelvis</p></div></p>
                        <h3><a href="#">Target Population</a></h3>
                    <p><div class="content_para"><p>Adult patients with transitional cell carcinoma (urothelial carcinoma) of the ureter and/or renal pelvis</p></div></p>
                        <h3><a href="#">Interventions and Practices Considered</a></h3>
                    <p><div class="content_para"><p><strong>Diagnosis/Evaluation</strong></p>
<ol style="list-style-type: decimal;" start="1">
    <li>Laboratory investigations
    <ul style="list-style-type: disc;">
        <li>Urine cytology </li>
        <li>Complete blood count </li>
        <li>Basic metabolic panel (renal function) </li>
    </ul>
    </li>
    <li>Imaging studies
    <ul style="list-style-type: disc;">
        <li>Intravenous pyelogram (IVP) </li>
        <li>Computed tomography (CT) urography </li>
        <li>Retrograde pyelogram </li>
        <li>Ureteroscopy </li>
        <li>Magnetic resonance imaging (MRI) urogram (upper tract collecting system) </li>
        <li>Cystoscopy </li>
        <li>Chest x-ray </li>
        <li>Renal scan (optional) </li>
        <li>Bone scan if abnormal enzymes or if bone signs/symptoms </li>
    </ul>
    </li>
</ol>
<p><strong>Treatment/Management</strong></p>
<ol style="list-style-type: decimal;" start="1">
    <li>Nephroureterectomy with cuff of bladder or nephron-sparing procedure </li>
    <li>Regional lymph node dissection </li>
    <li>Endoscopic resection </li>
    <li>Excision and ureteroureterostomy (low-grade mid-ureter) </li>
    <li>Distal ureterectomy </li>
    <li>Neoadjuvant or adjuvant chemotherapy (cisplatinum-based contamination therapy) </li>
    <li>Follow-up </li>
</ol></div></p>
                        <h3><a href="#">Major Outcomes Considered</a></h3>
                    <p><ul style="list-style-type: disc;">
    <li>Survival rate (5-year, overall, recurrence-free, disease-free) </li>
    <li>Response rate </li>
    <li>Recurrence rate </li>
    <li>Cancer-specific mortality </li>
</ul></p>

            </div>
                <h2 id="405" class="accordion-title section-405 is-active" role="tab" aria-expanded="true"><a href="#">Methodology</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Methods Used to Collect/Select the Evidence</a></h3>
                    <p>Searches of Electronic Databases</p>
                        <h3><a href="#">Description of Methods Used to Collect/Select the Evidence</a></h3>
                    <p><div class="content_para"><p><strong>Research Questions</strong></p>
<p>Specific research questions to be addressed by the guideline document were formulated by the guideline lead(s) and Knowledge Management (KM) Specialist using the PICO question format (patient or population, intervention, comparisons, outcomes).</p>
<p><strong>Guideline Questions</strong></p>
<ul style="list-style-type: disc;">
    <li>What staging investigations are required for patients with upper tract tumours? </li>
    <li>What are the appropriate treatment options (i.e., surgery, systemic therapy, etc.) for patients with upper tract tumours? </li>
    <li>What is a reasonable follow-up strategy for patients who have completed treatment for upper tract tumours? </li>
</ul>
<p><strong>Search Strategy</strong></p>
<p>The PubMed database was searched for relevant literature using the following search terms: (renal pelvis AND neoplasm) OR (ureter AND neoplasm) AND transitional cell carcinoma. Results were limited to clinical trials, practice guidelines, systematic reviews, and meta-analyses published from 1991 through 2012 March. The Medline database was also searched using the MeSH terms "Carcinoma, Transitional Cell" with subheadings drug therapy, radiotherapy, surgery and therapy, combined with the MeSH terms "Kidney Pelvis" and "Urinary Bladder Neoplasms." Results were limited to literature published between 1990 and 2012 March. Based on feedback from the working group, the Medline database was searched subsequently using the MeSH terms "Carcinoma, Transitional Cell" AND "Neoadjuvant therapy" with subheading drug therapy. Results were limited to literature published from 1990 through 2012 July. Non-relevant publications were excluded, as well as any publications that did not report survival outcomes.</p>
<p>The National Comprehensive Cancer Network (NCCN), British Columbia Cancer Agency (BCCA), European Society of Medical Oncology (ESMO), National Institute for Health and Care Excellence (NICE), American Society of Clinical Oncology (ASCO), Scottish Intercollegiate Guidelines Network (SIGN), Cancer Council Australia (CCA), and Cancer Care Ontario (CCO) websites were searched for guidelines on the management of upper tract tumours.</p></div></p>
                        <h3><a href="#">Number of Source Documents</a></h3>
                    <p><div class="content_para"><p>A total of 3 guidelines, 1 meta-analysis, and 22 clinical studies (i.e., retrospective case series, prospective cohort studies, phase II-III trials) were included.</p></div></p>
                        <h3><a href="#">Methods Used to Assess the Quality and Strength of the Evidence</a></h3>
                    <p>Not stated</p>
                        <h3><a href="#">Rating Scheme for the Strength of the Evidence</a></h3>
                    <p><div class="content_para"><p>Not applicable</p></div></p>
                        <h3><a href="#">Methods Used to Analyze the Evidence</a></h3>
                    <p>Review of Published Meta-Analyses</p>
                    <p>Systematic Review with Evidence Tables</p>
                        <h3><a href="#">Description of the Methods Used to Analyze the Evidence</a></h3>
                    <p><div class="content_para"><p>Evidence was selected and reviewed by a working group comprised of members from the Alberta Provincial Genitourinary Tumour Team and a Knowledge Management (KM) Specialist from the Guideline Utilization Resource Unit (GURU). A detailed description of the methodology followed during the guideline development process can be found in the GURU Handbook (see the "Availability of Companion Documents" field).</p>
<p><strong>Evidence Tables</strong></p>
<p>Evidence tables containing the first author, year of publication, patient group/stage of disease, methodology, and main outcomes of interest are assembled using the studies identified in the literature search. Existing guidelines on the topic are assessed by the KM Specialist using portions of the Appraisal of Guidelines Research and Evaluation (AGREE) II instrument (<a href="/web/20180712210624/https://www.guideline.gov/Home/Disclaimer?id=48139&amp;contentType=summary&amp;redirect=http%3a%2f%2fwww.agreetrust.org" title="AGREE Trust Web site">http://www.agreetrust.org</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180712210624im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>) and those meeting the minimum requirements are included in the evidence document. Due to limited resources, GURU does not regularly employ the use of multiple reviewers to rank the level of evidence; rather, the methodology portion of the evidence table contains the pertinent information required for the reader to judge for himself the quality of the studies.</p></div></p>
                        <h3><a href="#">Methods Used to Formulate the Recommendations</a></h3>
                    <p>Expert Consensus</p>
                        <h3><a href="#">Description of Methods Used to Formulate the Recommendations</a></h3>
                    <p><div class="content_para"><p><strong>Formulating Recommendations</strong></p>
<p>The working group members formulated the guideline recommendations based on the evidence synthesized by the Knowledge Management (KM) Specialist during the planning process, blended with expert clinical interpretation of the evidence. As detailed in the Guideline Utilization Resource Unit Handbook (see the "Availability of Companion Documents" field), the working group members may decide to adopt the recommendations of another institution without any revisions, adapt the recommendations of another institution or institutions to better reflect local practices, or develop their own set of recommendations by adapting some, but not all, recommendations from different guidelines.</p>
<p>The degree to which a recommendation is based on expert opinion of the working group and/or the Provincial Tumour Team members is explicitly stated in the guideline recommendations. Similar to the American Society of Clinical Oncology (ASCO) methodology for formulating guideline recommendations, the Guideline Utilization Resource Unit (GURU) does not use formal rating schemes for describing the strength of the recommendations, but rather describes, in conventional and explicit language, the type and quality of the research and existing guidelines that were taken into consideration when formulating the recommendations.</p></div></p>
                        <h3><a href="#">Rating Scheme for the Strength of the Recommendations</a></h3>
                    <p><div class="content_para"><p>Not applicable</p></div></p>
                        <h3><a href="#">Cost Analysis</a></h3>
                    <p><div class="content_para"><p>A formal cost analysis was not performed and published cost analyses were not reviewed.</p></div></p>
                        <h3><a href="#">Method of Guideline Validation</a></h3>
                    <p>Internal Peer Review</p>
                        <h3><a href="#">Description of Method of Guideline Validation</a></h3>
                    <p><div class="content_para"><p>This guideline was reviewed and endorsed by the Alberta Provincial Genitourinary Tumour Team.</p>
<p>When the draft guideline document has been completed, revised, and reviewed by the Knowledge Management (KM) Specialist and the working group members, it is sent to all members of the Provincial Tumour Team for review and comment. This step ensures that those intended to use the guideline have the opportunity to review the document and identify potential difficulties for implementation before the guideline is finalized. Depending on the size of the document, and the number of people it is sent to for review, a deadline of one to two weeks will usually be given to submit any feedback. Ideally, this review will occur prior to the annual Provincial Tumour Team meeting, and a discussion of the proposed edits will take place at the meeting. The working group members will then make final revisions to the document based on the received feedback, as appropriate. Once the guideline is finalized, it will be officially endorsed by the Provincial Tumour Team Lead and the Executive Director of Provincial Tumour Programs.</p></div></p>

            </div>
                <h2 id="424" class="accordion-title section-424 is-active" role="tab" aria-expanded="true"><a href="#">Evidence Supporting the Recommendations</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Type of Evidence Supporting the Recommendations</a></h3>
                    <p><div class="content_para"><p>The type of evidence supporting the recommendations is not specifically stated.</p></div></p>

            </div>
                <h2 id="427" class="accordion-title section-427 is-active" role="tab" aria-expanded="true"><a href="#">Benefits/Harms of Implementing the Guideline Recommendations</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Potential Benefits</a></h3>
                    <p><div class="content_para"><p>Appropriate work-up and treatment of upper tract urothelial tumours</p></div></p>
                        <h3><a href="#">Potential Harms</a></h3>
                    <p><div class="content_para"><p>Not stated</p></div></p>

            </div>
                <h2 id="432" class="accordion-title section-432 is-active" role="tab" aria-expanded="true"><a href="#">Qualifying Statements</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Qualifying Statements</a></h3>
                    <p><div class="content_para"><p>The recommendations contained in this guideline are a consensus of the Alberta Provincial Genitourinary Tumour Team and are a synthesis of currently accepted approaches to management, derived from a review of relevant scientific literature. Clinicians applying these guidelines should, in consultation with the patient, use independent medical judgment in the context of individual clinical circumstances to direct care.</p></div></p>

            </div>
                <h2 id="434" class="accordion-title section-434 is-active" role="tab" aria-expanded="true"><a href="#">Implementation of the Guideline</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Description of Implementation Strategy</a></h3>
                    <p><ul style="list-style-type: disc;">
    <li>Present the guideline at the local and provincial tumour team meetings and weekly rounds. </li>
    <li>Post the guideline on the Alberta Health Services Web site. </li>
    <li>Send an electronic notification of the new guideline to all members of CancerControl Alberta. </li>
</ul></p>

            </div>
                <h2 id="439" class="accordion-title section-439 is-active" role="tab" aria-expanded="true"><a href="#">Institute of Medicine (IOM) National Healthcare Quality Report Categories</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">IOM Care Need</a></h3>
                    <p>Getting Better</p>
                    <p>Living with Illness</p>
                        <h3><a href="#">IOM Domain</a></h3>
                    <p>Effectiveness</p>

            </div>
                <h2 id="442" class="accordion-title section-442 is-active" role="tab" aria-expanded="true"><a href="#">Identifying Information and Availability</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">Bibliographic Source(s)</a></h3>
                    <p><table><tr><td>Alberta Provincial Genitourinary Tumour Team. Upper tract urothelial tumours. Edmonton (Alberta): CancerControl Alberta; 2013 Apr. 10 p.&nbsp;(Clinical practice guideline; no. GU-008).&nbsp; [22 references]</td></tr></table></p>
                        <h3><a href="#">Adaptation</a></h3>
                    <p><div class="content_para"><p>Not applicable: The guideline was not adapted from another source.</p></div></p>
                        <h3><a href="#">Date Released</a></h3>
                    <p>2013 Apr</p>
                        <h3><a href="#">Guideline Developer(s)</a></h3>
                    <p>CancerControl Alberta - State/Local Government Agency [Non-U.S.]</p>
                        <h3><a href="#">Source(s) of Funding</a></h3>
                    <p><div class="content_para"><p>CancerControl Alberta</p></div></p>
                        <h3><a href="#">Guideline Committee</a></h3>
                    <p><div class="content_para"><p>Alberta Provincial Genitourinary Tumour Team</p></div></p>
                        <h3><a href="#">Composition of Group That Authored the Guideline</a></h3>
                    <p><div class="content_para"><p>Members of the Alberta Provincial Genitourinary Tumour Team include medical oncologists, radiation oncologists, urologists, pathologists, nurses, and pharmacists.</p></div></p>
                        <h3><a href="#">Financial Disclosures/Conflicts of Interest</a></h3>
                    <p><div class="content_para"><p>Participation of members of the Alberta Provincial Genitourinary Tumour Team in the development of this guideline has been voluntary and the authors have not been remunerated for their contributions. There was no direct industry involvement in the development or dissemination of this guideline. CancerControl Alberta recognizes that although industry support of research, education and other areas is necessary in order to advance patient care, such support may lead to potential conflicts of interest. Some members of the Alberta Provincial Genitourinary Tumour Team are involved in research funded by industry or have other such potential conflicts of interest. However the developers of this guideline are satisfied it was developed in an unbiased manner.</p></div></p>
                        <h3><a href="#">Guideline Status</a></h3>
                    <p><div class="content_para"><p>This is the current release of the guideline.</p></div></p>
                        <h3><a href="#">Guideline Availability</a></h3>
                    <p><div class="content_para"><p>Available from the <a href="/web/20180712210624/https://www.guideline.gov/Home/Disclaimer?id=48139&amp;contentType=summary&amp;redirect=http%3a%2f%2fwww.albertahealthservices.ca%2fassets%2finfo%2fhp%2fcancer%2fif-hp-cancer-guide-gu008-upper-tract.pdf" title="Alberta Health Services Web site">Alberta Health Services Web site</a>&nbsp;<img alt="External Web Site Policy" src="/web/20180712210624im_/https://www.guideline.gov/UI/images/icon_externallink.gif"/>.</p></div></p>
                        <h3><a href="#">Availability of Companion Documents</a></h3>
                    <p><div class="content_para"><p>The following is available:</p>
<ul style="list-style-type: disc;">
    <li>Guideline utilization resource unit handbook. Edmonton (Alberta): CancerControl Alberta; 2013 Jan. 5 p. </li>
</ul></div></p>
                        <h3><a href="#">Patient Resources</a></h3>
                    <p><div class="content_para"><p>None available</p></div></p>
                        <h3><a href="#">NGC Status</a></h3>
                    <p><div class="content_para"><p>This NGC summary was completed by ECRI Institute on August 12, 2014. The information was verified by the guideline developer on September 25, 2014.</p></div></p>
                        <h3><a href="#">Copyright Statement</a></h3>
                    <p><div class="content_para"><p>This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.</p></div></p>

            </div>
                <h2 id="99999" class="accordion-title section-99999 is-active" role="tab" aria-expanded="true"><a href="#">Disclaimer</a></h2>
            <div class="accordion-panel is-active" role="tabpanel">
                        <h3><a href="#">NGC Disclaimer</a></h3>
                    <p><p>The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.</p> 
<p>All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.</p> 
<p>Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the <a href="/web/20180712210624/https://www.guideline.gov/help-and-about/summaries/inclusion-criteria">NGC Inclusion Criteria</a>.</p> 
<p>NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.</p> 
<p>Readers with questions regarding guideline content are directed to contact the guideline developer.</p></p>

            </div>

    </div>
    <!-- /.accordion-container -->

<!-- ASIDE -->
<!-- FOOTER -->






		</div><!-- /.article -->

	</div><!-- /.content -->

	
			<div class="aside">
				

    <!-- About NGC -->
    <div class="info-block">
            <h3 class="info prefix-icon large-icon">About NGC Guideline Summaries</h3>
            <p>NGC provides structured summaries containing information from clinical practice guidelines.</p>
            <ul>
                <li><a href="/web/20180712210624/https://www.guideline.gov/help-and-about/summaries/inclusion-criteria" class="internal-link">Inclusion Criteria</a></li>
                <li><a href="/web/20180712210624/https://www.guideline.gov/help-and-about/summaries/template-of-guideline-attributes" class="internal-link">Template of Guideline Attributes</a></li>
                <li><a href="/web/20180712210624/https://www.guideline.gov/help-and-about/summaries/classification-scheme" class="internal-link">Classification Scheme</a></li>
            </ul>
            <p><a href="/web/20180712210624/https://www.guideline.gov/help-and-about/summaries/faqs" class="help-button">Guideline Summary FAQs</a></p>

    </div>
    <!-- /info-block -->

    <!-- Guideline Synthesis -->

    <!-- HHS Block -->

    <!-- Related Content -->


    <hr>

    <!-- New on NGC -->
    <div class="subscribe-header">
        <h3 class="subscribe-title">New on NGC</h3>
        <ul class="subscribe-links">
            <li><a href="/web/20180712210624/https://www.guideline.gov/subscribe" class="newsletter"><span class="subscribe-links-label">Get Email Alerts</span></a></li>
            <li><a href="/web/20180712210624/https://www.guideline.gov/rssFiles/ngc_newthisweek.xml" class="rss"><span class="subscribe-links-label">RSS Feed</span></a></li>
        </ul>
    </div>
    <!-- /.subscribe-header -->
        <h5 class="prefix-icon guideline news-list-category-label">Guideline Summaries</h5>
        <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011378</li>
            <li>2017 Oct</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180712210624/https://www.guideline.gov/summaries/summary/51300/mental-health-care-in-the-perinatal-period-australian-clinical-practice-guideline">Mental health care in the perinatal period: Australian clinical practice guideline.</a></p>
    </div>
    <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011372</li>
            <li>2015</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180712210624/https://www.guideline.gov/summaries/summary/51294/clinical-practice-guideline-on-systemic-lupus-erythematosus">Clinical practice guideline on systemic lupus erythematosus.</a></p>
    </div>
    <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011385</li>
            <li>2018 Mar</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180712210624/https://www.guideline.gov/summaries/summary/51326/vadod-clinical-practice-guideline-for-the-management-of-pregnancy">VA/DoD clinical practice guideline for the management of pregnancy.</a></p>
    </div>
    <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011376</li>
            <li>2018 Feb</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180712210624/https://www.guideline.gov/summaries/summary/51298/clinical-pharmacogenetics-implementation-consortium-cpic-guideline-for-dihydropyrimidine-dehydrogenase-genotype-and-fluoropyrimidine-dosing-2017-update">Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update.</a></p>
    </div>
    <div class="list-item-small">
        <ul class="item-meta">
            <li> NGC:011370</li>
            <li>2017 Dec</li>
        </ul>
       
            <p><a class="" target="" href="/web/20180712210624/https://www.guideline.gov/summaries/summary/51292/the-implementation-of-targeted-temperature-management-an-evidencebased-guideline-from-the-neurocritical-care-society">The implementation of targeted temperature management: an evidence-based guideline from the Neurocritical Care Society.</a></p>
    </div>

    <a class="block-link" href="/web/20180712210624/https://www.guideline.gov/new-this-week/index">
        <h3>New This Week </h3>
        <p>View more and sign up for our Newsletter</p>
    </a>
    <!-- Adobe Reader -->
    <p><a href="/web/20180712210624/https://www.guideline.gov/disclaimer?id=48139&amp;contentType=summary&amp;redirect=http%3A%2F%2Fget.adobe.com%2Freader%2F" class="external-link">Get Adobe Reader</a></p>

			</div><!-- /.aside -->
		</div><!-- /.aside-container -->

	<!-- BACK TO TOP -->
	
	
	



    <!-- COMMENTS -->
    

</div><!-- /.main -->

	</main>

	<!-- FOOTER -->
	<div class="footer" id="footer">

		<div class="footer-grid-container">
			<!-- Header -->
			<div class="footer-header">
				<a href="#" class="footer-logo">
			 		<picture>
					  	<source type="image/svg+xml" srcset="/web/20180712210624im_/https://www.guideline.gov/UI/images/logo_NGC_footer.svg">
					  	<img src="/web/20180712210624im_/https://www.guideline.gov/UI/images/logo_NGC_footer.png" alt="NGC">
					</picture>
				</a>
			</div><!-- /.footer-header -->

			<!-- Content -->
			<div class="footer-content">
				<div class="footer-nav">
					<ul class="level-1">
						<li><a href="/web/20180712210624/https://www.guideline.gov/">Home</a></li>
		                <li><a href="/web/20180712210624/https://www.guideline.gov/new-this-week/index">New This Week</a></li>
						<li><a href="/web/20180712210624/https://www.guideline.gov/browse/organization" class="parent-link">Guideline Summaries</a></li>
<li><a href="/web/20180712210624/https://www.guideline.gov/syntheses/index">Guideline Syntheses</a></li>						<li><a href="/web/20180712210624/https://www.guideline.gov/expert">Expert Commentaries</a></li>
		                <li><a href="/web/20180712210624/https://www.guideline.gov/matrix">Matrix Tool</a></li>
						<li><a href="/web/20180712210624/https://www.guideline.gov/summaries/submit">Submit Guidelines</a></li>
						<li><a href="/web/20180712210624/https://www.guideline.gov/help-and-about">Help &amp;&nbsp;About</a></li>
					</ul>
					<ul class="level-2">
						<li><a href="/web/20180712210624/https://www.guideline.gov/contact-us">Contact Us</a></li>
						<li><a href="/web/20180712210624/https://www.guideline.gov/rss">RSS</a></li>
					    <li><a href="/web/20180712210624/https://www.guideline.gov/site-map">Site Map</a></li>
                        <li><a href="/web/20180712210624/https://www.guideline.gov/browse/related">Related NQMC Measures</a></li>
                        <li><a href="/web/20180712210624/https://www.guideline.gov/help-and-about/about/editorial-board">Editorial Board</a></li>
                        <li><a href="/web/20180712210624/https://www.guideline.gov/help-and-about/general/web-site-credits">Web Site Credits</a></li>
                        <li><a href="/web/20180712210624/https://www.guideline.gov/help-and-about/general/disclaimer">Disclaimer</a></li>
						<li><a href="/web/20180712210624/https://www.guideline.gov/help-and-about/general/privacy">Privacy Policy</a></li>
                        <li><a href="/web/20180712210624/https://www.guideline.gov/help-and-about/technical/accessibility">Accessibility</a></li>	
                        <li><a href="/web/20180712210624/https://www.guideline.gov/help-and-about/technical/for-web-developers">For Web Developers</a></li>
					</ul>
				</div><!-- /.footer-nav -->
			</div><!-- /.footer-content -->

			<!-- Aside -->
			<div class="footer-aside">
				<h5 class="footer-partner-link-header">Visit our partner sites</h5>
				<ul class="footer-partner-links">
				    <li><!-- NQMC footer link -->
						<a href="https://web.archive.org/web/20180712210624/https://www.qualitymeasures.ahrq.gov/" target="_blank" class="partner-button nqmc">
							<span class="partner-logo">
								<picture>
							    	<source type="image/svg+xml" srcset="/web/20180712210624im_/https://www.guideline.gov/UI/images/logo_footerlink_nqmc.svg">
									<img src="/web/20180712210624im_/https://www.guideline.gov/UI/images/logo_footerlink_nqmc.png" alt="National Quality Measures Clearinghouse"/>
								</picture>
							</span>
						</a>
					</li><!--/MQMC footer Link -->
					<li><!-- HHS footer link --> 
						<a href="https://web.archive.org/web/20180712210624/https://www.qualitymeasures.ahrq.gov/hhs/index.aspx" target="_blank" class="partner-button hhs">
							<span class="partner-logo">
								<picture>
								    <source type="image/svg+xml" srcset="/web/20180712210624im_/https://www.guideline.gov/UI/images/logo_footerlink_hmis.svg">
								    <img src="/web/20180712210624im_/https://www.guideline.gov/UI/images/logo_footerlink_hmis.png" alt="HHS Measures Inventory"/>
								</picture>
							</span>
						</a>
					</li><!--/HHS footer link -->
				</ul>
			</div><!-- /.footer-aside -->

		</div><!-- /.footer-grid-container -->

	</div><!-- /.footer -->

	
	<!-- AHRQ FOOTER -->
	<div id="ahrq-footer">

		<!-- FIRST -->
		<div class="ahrq-first-footer">
			<div class="column">
			<div class="ahrq-footer-grid-container">
				<div class="ahrq-footer-left">
					<p><a href="https://web.archive.org/web/20180712210624/http://www.ahrq.gov/index.html" class="ahrq-footer-logo" target="_blank">AHRQ</a></p>
				</div><!-- /.ahrq-footer-left -->
				<div class="ahrq-footer-center">
					<ul>
						<li><a href="https://web.archive.org/web/20180712210624/http://www.ahrq.gov/policy/electronic/accessibility/index.html" target="_blank">Accessibility</a></li>
						<li><a href="https://web.archive.org/web/20180712210624/http://www.ahrq.gov/policy/electronic/disclaimers/index.html" target="_blank">Disclaimers</a></li>
						<li><a href="https://web.archive.org/web/20180712210624/http://www.ahrq.gov/policy/eeo/index.html" target="_blank">EEO</a></li>
						<li><a href="https://web.archive.org/web/20180712210624/http://www.ahrq.gov/policy/foia/index.html" target="_blank">FOIA</a></li>
						<li><a href="https://web.archive.org/web/20180712210624/http://www.hhs.gov/web/governance/digital-strategy/index.html" target="_blank">HHS Digital Strategy</a></li>
						<li><a href="https://web.archive.org/web/20180712210624/http://oig.hhs.gov/" target="_blank">Inspector General</a></li>
						<li><a href="https://web.archive.org/web/20180712210624/http://www.ahrq.gov/policy/electronic/plain-writing/index.html" target="_blank">Plain Writing Act</a></li>
						<li><a href="https://web.archive.org/web/20180712210624/http://www.ahrq.gov/policy/electronic/privacy/index.html" target="_blank">Privacy Policy</a></li>
						<li><a href="https://web.archive.org/web/20180712210624/http://www.ahrq.gov/policy/electronic/about/policyix.html" target="_blank">Electronic Policies</a></li>
						<li><a href="https://web.archive.org/web/20180712210624/http://www.hhs.gov/plugins.html" target="_blank">Viewers &amp; Players</a></li>
					</ul>
				</div><!-- /.ahrq-footer-center -->
				<div class="ahrq-footer-right">
					<h3>Get Social</h3>
					<ul class="ahrq-social">
						<li><a href="https://web.archive.org/web/20180712210624/http://www.facebook.com/" target="_blank" class="facebook"><span class="screen-reader-text">Facebook</span></a></li>
						<li><a href="https://web.archive.org/web/20180712210624/http://www.twitter.com/" target="_blank" class="twitter"><span class="screen-reader-text">Twitter</span></a></li>
						<li><a href="https://web.archive.org/web/20180712210624/http://www.linkedin.com/" target="_blank" class="linkedin"><span class="screen-reader-text">LinkedIn</span></a></li>
						<li><a href="https://web.archive.org/web/20180712210624/http://www.youtube.com/" target="_blank" class="youtube"><span class="screen-reader-text">YouTube</span></a></li>
					</ul>
				</div><!-- /.ahrq-footer-right -->
			</div><!-- /.ahrq-footer-grid-container -->
			</div><!-- /.column -->
		</div><!-- /.first-footer -->

		<!-- SECOND -->
		<div class="ahrq-second-footer">
			<div class="column">
			<div class="ahrq-footer-grid-container">
				<div class="ahrq-footer-left">
					<ul>
						<li><a href="https://web.archive.org/web/20180712210624/http://www.ahrq.gov/index.html" target="_blank" class="ahrq-footer-home-link"><span class="screen-reader-text">AHRQ Home</span></a></li>
						<li><a href="https://web.archive.org/web/20180712210624/http://www.ahrq.gov/cpi/about/index.html" target="_blank">About Us</a></li>
						<li><a href="https://web.archive.org/web/20180712210624/http://www.ahrq.gov/cpi/about/careers/index.html" target="_blank">Careers</a></li>
						<li><a href="https://web.archive.org/web/20180712210624/http://www.ahrq.gov/contact/index.html" target="_blank">Contact Us</a></li>
						<li><a href="https://web.archive.org/web/20180712210624/http://www.ahrq.gov/Sitemap.html" target="_blank">Sitemap</a></li>
						<li><a href="https://web.archive.org/web/20180712210624/https://info.ahrq.gov/" target="_blank">FAQ</a></li>
					</ul>	
				</div><!-- /.ahrq-footer-left -->
				<div class="ahrq-footer-center">
					<ul>
						<li><a href="https://web.archive.org/web/20180712210624/http://www.ahrq.gov/health-care-information/index.html" target="_blank">Health Care Information</a></li>
						<li><a href="https://web.archive.org/web/20180712210624/http://www.ahrq.gov/patients-consumers/index.html" target="_blank">For Patients &amp; Consumers</a></li>
						<li><a href="https://web.archive.org/web/20180712210624/http://www.ahrq.gov/professionals/index.html" target="_blank">For Professionals</a></li>
						<li><a href="https://web.archive.org/web/20180712210624/http://www.ahrq.gov/policymakers/index.html" target="_blank">For Policymakers</a></li>
						<li><a href="https://web.archive.org/web/20180712210624/http://www.ahrq.gov/research/index.html" target="_blank">Research Tools &amp; Data</a></li>
						<li><a href="https://web.archive.org/web/20180712210624/http://www.ahrq.gov/funding/index.html" target="_blank">Funding &amp; Grants</a></li>
						<li><a href="https://web.archive.org/web/20180712210624/http://www.ahrq.gov/cpi/index.html" target="_blank">Offices, Centers &amp; Programs</a></li>
						<li><a href="https://web.archive.org/web/20180712210624/http://www.ahrq.gov/news/index.html" target="_blank">News &amp; Events</a></li>
					</ul>
				</div><!-- /.ahrq-footer-center -->
				<div class="ahrq-footer-right">
					<ul>
						<li><a href="https://web.archive.org/web/20180712210624/http://www.hhs.gov/" target="_blank">U.S. Department of Health &amp; Human Services</a></li>
						<li><a href="https://web.archive.org/web/20180712210624/http://www.whitehouse.gov/" target="_blank">The White House</a></li>
						<li><a href="https://web.archive.org/web/20180712210624/http://www.usa.gov/" target="_blank">USA.gov: The U.S. Government's Official Web Portal   </a></li>
					</ul>
					<p class="ahrq-address">
						<strong>Agency for Healthcare Research&nbsp;and&nbsp;Quality</strong>
					    <br/>5600 Fishers Lane
					    <br/>Rockville, MD 20857
					    <br/><strong>Telephone:</strong> (301) 427-1364
					</p>
				</div><!-- /.ahrq-footer-right -->
			</div><!-- /.ahrq-footer-grid-container -->
			</div><!-- /.column -->
		</div><!-- /.second-footer -->
	</div><!-- /#ahrq-footer -->


	
	<!-- SCRIPTS -->
	
<script src="//web.archive.org/web/20180712210624js_/https://ajax.googleapis.com/ajax/libs/jquery/1.6.3/jquery.min.js" type="text/javascript"></script>
<script type="text/javascript">
if(!window.jQuery){
document.write('<script src="/cassette.axd/script/cdd67f922f9d413eaccb759182297335f87c3ff7/UI/js/jquery.js" type="text/javascript"><\/script>');
}
</script>
<script src="/web/20180712210624js_/https://www.guideline.gov/cassette.axd/script/595952c286b7fd52f0737b6f62085709be93156a/bodyJS" type="text/javascript"></script>

    
</body>
</html>
<!--
     FILE ARCHIVED ON 21:06:24 Jul 12, 2018 AND RETRIEVED FROM THE
     INTERNET ARCHIVE ON 17:47:33 Jul 15, 2018.
     JAVASCRIPT APPENDED BY WAYBACK MACHINE, COPYRIGHT INTERNET ARCHIVE.

     ALL OTHER CONTENT MAY ALSO BE PROTECTED BY COPYRIGHT (17 U.S.C.
     SECTION 108(a)(3)).
-->
<!--
playback timings (ms):
  LoadShardBlock: 124.989 (3)
  esindex: 0.008
  captures_list: 149.019
  CDXLines.iter: 18.751 (3)
  PetaboxLoader3.datanode: 85.768 (4)
  exclusion.robots: 0.175
  exclusion.robots.policy: 0.164
  RedisCDXSource: 1.086
  PetaboxLoader3.resolve: 45.624
  load_resource: 85.796
-->